Subsequently, primary cells of 15 MDS/AML patients, whose clinical and cytogenetic features are illustrated in Table 3, were used to evaluate the effect of DFX on the expression of the CDKN1A and PUMA genes. The gene discussed is CDKN1A; the disease is myelodysplastic syndrome.